PLoS ONE (Jan 2023)

Recruitment strategies and HPV self-collection return rates for under-screened women for cervical cancer prevention.

  • Jennifer S Smith,
  • Olivia M Vaz,
  • Charley E Gaber,
  • Andrea C Des Marais,
  • Bhavika Chirumamilla,
  • Lori Hendrickson,
  • Lynn Barclay,
  • Alice R Richman,
  • Xian Brooks,
  • Anna Pfaff,
  • Noel T Brewer

DOI
https://doi.org/10.1371/journal.pone.0280638
Journal volume & issue
Vol. 18, no. 3
p. e0280638

Abstract

Read online

In the United States, medically underserved women carry a heavier burden of cancer incidence and mortality, yet are largely underrepresented in cancer prevention studies. My Body, My Test is a n observational cohort, multi-phase cervical cancer prevention study in North Carolina that recruited low-income women, aged 30-65 years and who had not undergone Pap testing in ≥ 4 years. Participants were offered home-based self-collection of cervico-vaginal samples for primary HPV testing. Here, we aimed to describe the recruitment strategies utilized by study staff, and the resulting recruitment and self-collection kit return rates for each specific recruitment strategy. Participants were recruited through different approaches: either direct (active, staff-effort intensive) or indirect (passive on the part of study staff). Of a total of 1,475 individuals screened for eligibility, 695 were eligible (47.1%) and 487 (70% of eligible) participants returned their self-collection kit. Small media recruitment resulted in the highest number of individuals found to be study eligible, with a relatively high self-collection kit return of 70%. In-clinic in-reach resulted in a lower number of study-eligible women, yet had the highest kit return rate (90%) among those sent kits. In contrast, 211 recruitment which resulted in the lowest kit return of 54%. Small media, word of mouth, and face-to-face outreach resulted in self-collection kit return rates ranging from 72 to 79%. The recruitment strategies undertaken by study staff support the continued study of reaching under-screened populations into cervical cancer prevention studies.